Knee Osteoarthritis Clinical Trial
— CANOOfficial title:
Comparative Effectiveness of High-intensity Aerobic Exercise and Biomechanical Neuromuscular Exercise for Treatment of Knee Osteoarthritis: A Randomised Open Label Trial
The study aims to compare the effects of an education and High Intensity Interval Training program (eHIIT) with the widely used Neuromuscular Exercise and education program (NEMEX-e) on knee OA symptoms and risk factors for cardiovascular disease in people with knee OA and at least one risk factor for developement of cardiovascular disease. The main research questions the study aims to answer are: - Is the eHIIT program better than the NEMEX-e program for reducing the risk of cardiovascular disease? - Are the two programs equally good at providing improvement in knee symptoms?
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 31, 2026 |
Est. primary completion date | June 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18- years - Diagnosis of tibiofemoral knee OA according to the American College of Rheumatology criteria - Radiographically confirmed diagnosis of tibiofemoral OA based on radiographs not older than 6 months. - Average knee pain level = 4 (0=No pain and 10=Worst pain) over the past week (7 days) - At least one of following risk factors for development of cardiovascular disease: - Body mass index = 30 kg/m2 - Hypertension (or in treatment of): Systolic = 135 and/or diastolic = 85 mm Hg - Elevated HbA1c (or in treatment of): = 130.7 mg/dL (44 mmol/mol) - Elevated Triglycerides (or in treatment of): = 150 mg/dL (1.7 mmol/L) - Elevated Cholesterol (or in treatment of) (Low density lipides, LDL): LDL = 54 mg/dL (3.0 mmol/L) Exclusion Criteria: - Contraindication to exercise (e.g., resting systolic blood pressure > 200 or diastolic blood pressure > 115, acute or reoccurring chest pain) - Unstable body weight the last 3 months (gain/loss outside +/- 5 kg) - Planned weight loss (non-pharmacological, pharmacological, and surgical) during study participation - Known current cancer - Major cardiovascular event within the last 5 years - Insulin dependent type 1 or type 2 diabetes - Psoriatic, rheumatoid, or gouty arthritis disease - Generalized pain syndromes such as fibromyalgia - Lumbar or cervical nerve root compression syndromes - Scheduled surgery during study participation - Treatment with biological medication - Impairments that prevent performance in high intensity aerobic exercise - Current or planned participation in other health research intervention studies - Pregnant/considering pregnancy - Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as a large knee joint effusion, uncontrolled diabetes/hypertension, psychiatric or cognitive disorders, language barriers, or opiate dependency. |
Country | Name | City | State |
---|---|---|---|
Denmark | The Parker Institute, Frederiksberg Hospital | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Frederiksberg University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Knee-related Quality of Life | The Knee injury and Osteoarthritis Outcome Score (KOOS) quality of life subscale (KOOS-QoL), a disease-specific patient-reported instrument designed to assess knee-related quality of life in patients with knee osteoarthritis.
The KOOS-QoL subscale is scored on a 0-100 scale with 100 indicating best possible knee-related quality of life and 0 indicating worst possible knee-related quality of life. |
Baseline, week 8, week 12 and week 26 | |
Other | Knee Symptoms | The Knee injury and Osteoarthritis Outcome Score (KOOS) symptoms subscale (KOOS-symptoms), a disease-specific patient-reported instrument designed to knee symptoms in patients with knee osteoarthritis.
KOOS-symptom is scored on a 0-100 scale with indicating no symptoms and 0 indicating worst possible symptoms. |
Baseline, week 8, week 12 and week 26 | |
Other | Knee Function in Sports and Recreational activities | The Knee injury and Osteoarthritis Outcome Score (KOOS) Sports and Recreation subscale (KOOS-Sports/Recreation), a disease-specific patient-reported instrument designed to knee symptoms in patients with knee osteoarthritis.
KOOS-Sports/Recreation is scored on a 0-100 scale with indicating no symptoms and 0 indicating worst possible symptoms. |
Baseline, week 8, week 12 and week 26 | |
Other | The World Health Organisation - Five Well-Being Index (WHO-5) | Patient reported mental well-being will be obtained with the The World Health Organisation 5-Well-Being Index consisting of five questions each scored on a 0 to 5 scale.
Raw score: 0 represents worst possible well-being and 25 represents best possible well-being. Percentage score: 0 represents worst possible well-being and 100 represents best possible well-being. |
Baseline, week 8, week 12 and week 26 | |
Other | OMERACT-OARSI treatment responder criteria | A classification of patients as a positive responder based on the Outcome Measures in Rheumatology (OMERACT) and Osteoarthritis Research Society International (OARSI) (OMERACT-OARSI) responder criteria that classifies patients according to improvements in pain (co-primary outcome),function (secondary outcome) and patient global assessment (secondary outcome).
Each participant is classified as either a "responder" or a "non-responder" at each of the post-baseline follow-ups. |
Baseline, week 8, week 12 and week 26 | |
Other | Sleep quality using the global Single-item sleep quality scale (SQS) | Sleep quality will be obtained with the global Single-item sleep quality scale (SQS). SQS is scored on 0-10 scale with 0 representing worst possible sleep quality and 10 representing best possible sleep quality. | Baseline, week 8, week 12 and week 26 | |
Other | Nightly pain | Self-reported pain during the night is obtained on a 0-2 scale with 0=No nightly pain, 1=pain at movement or in certain positions, and 2=Pain even without movement. | Baseline, week 8, week 12 and week 26 | |
Other | Maximal aerobic capacity (VO2 peak) during a cardiopulmonary exercise test | A cardiopulmonary exercise test will be used to assess maximal aerobic capacity (VO2peak) measured in ml/min/kg. | Baseline, week 8, week 12 and week 26 | |
Other | Maximum work during a cardiopulmonary exercise test | The maximal work during the cardiopulmonary exercise test measured in Watts (W) | Baseline, week 8, week 12 and week 26 | |
Other | Respiratory exchange ratio (RER) during a cardiopulmonary exercise test | The respiratory exchange ratio (RER) during the cardiopulmonary exercise test is calculated as the ratio of carbon-dioxide production (VCO2) and oxygen consumption (VO2) | Baseline, week 8, week 12 and week 26 | |
Other | Maximal hear rate during a cardiopulmonary exercise test | The maximal heart rate during a cardiopulmonary exercise test is recorded as beats/min. | Baseline, week 8, week 12 and week 26 | |
Other | Lean body mass from a dual x-ray absorptiometry scan | Dual x-ray absorptiometry (DXA) will be used to assess lean body mass | Baseline, Week 12 and Week 26 | |
Other | Total fat mass from a dual x-ray absorptiometry scan | Dual x-ray absorptiometry (DXA) will be used to assess total fat mass. | Baseline, Week 12 and Week 26 | |
Other | Bone mineral density from a dual x-ray absorptiometry scan | Dual x-ray absorptiometry (DXA) will be used to assess bone density. | Baseline, Week 12 and Week 26 | |
Other | Hip and waist circumstance | The measurements are recorded in cm and measured during a clinical examination using a measurement tape and standardized procedures | Baseline, Week 12 and Week 26 | |
Other | Leg extensor power | Muscle power (force × velocity) of the lower limb of the target knee will be assessed using the Nottingham power rig. In a seated position, the participants will be instructed to push with a single leg against a plate at maximal effort/force. | Baseline, Week 12 and Week 26 | |
Other | Analgesics usage | The participants' use of over-the-counter paracetamol and ibuprofen will be recorded during an interview with an investigator. | Baseline, Week 12 and Week 26 | |
Other | Pressure pain sensitivity | A hand-held pressure algometer will used to assess pressure pain thresholds (PPTs). Pressure will be applied at a rate of approximately 30 kilopascal per second (kPa/s), with a 1 cm2 probe. All participants are instructed to push a button when they feel that the pressure becomes just barely painful. PPTs from the medial tibiofemoral joint space on the target knee and the contralateral elbow will be assessed | Baseline, Week 12 and Week 26 | |
Other | C-reactive protein concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Other | Interleukin 6 (IL6) concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Primary | Maximal oxygen consumption (VO2max) | Cardiopulmonary exercise test (CPET) on an ergometer bicycle for evaluation maximal oxygen consumption (VO2max) measured in ml/min/kg | Baseline and Week 12 | |
Primary | Knee pain | The Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale (KOOS-pain), a disease-specific patient-reported instrument designed to assess knee pain in patients with knee osteoarthritis.
The KOOS-pain subscale is scored on a 0-100 scale with 100 indicating no pain and 0 indicating extreme pain. |
Baseline and Week 12 | |
Secondary | Maximal oxygen consumption (VO2max) | Cardiopulmonary exercise test (CPET) on an ergometer bicycle for evaluation maximal oxygen consumption (VO2max) measured in ml/min/kg | Week 8 and week 26 | |
Secondary | Knee pain | The Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale (KOOS-pain), a disease-specific patient-reported instrument designed to assess knee pain in patients with knee osteoarthritis.
The KOOS-pain subscale is scored on a 0-100 scale with 100 indicating no pain and 0 indicating extreme pain. |
Week 8 and week 26 | |
Secondary | Body Mass | Body mass measured in kilograms using a scale | Baseline, Week 12 and Week 26 | |
Secondary | Blood Pressure | Systolic and Diastolic blood pressure | Baseline, Week 12 and Week 26 | |
Secondary | Triglyceride concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Secondary | Low Density Lipids (LDL) concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Secondary | Cholesterol concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Secondary | Glucose concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Secondary | HbA1c concentration | From a blood sample | Baseline, Week 12 and Week 26 | |
Secondary | Patient Global Assessment of disease Impact | Patient-reported degree of patient's perceived impact of their knee OA on their overall life will be obtained using a 100 mm analogue scale (VAS) with anchors: 0=" No impact" and 100 = "Worst imaginable impact". | Baseline, week 8, week 12 and week 26 | |
Secondary | Physical Functioning | The Knee injury and Osteoarthritis Outcome Score (KOOS) function subscale (KOOS-function), a disease-specific patient-reported instrument designed to assess physical functioning in patients with knee osteoarthritis.
The KOOS-function subscale is scored on a 0-100 scale with 100 indicating no functional impairments and 0 indicating extreme functional impairments. |
Baseline, week 8, week 12 and week 26 | |
Secondary | Health related quality of Life and physical and mental well-being (Short Form 12 (SF-12)) | The 12-item short form health questionnaire (SF-12) is a measure of physical and mental health.
The physical health component is scored between 0-72. The mental health component is scored between 0-70. For both components 0 mean a worse outcome. |
Baseline, week 8, week 12 and week 26 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04651673 -
Prescribed Knee Brace Treatments for Osteoarthritis of the Knee (Knee OA)
|
||
Completed |
NCT05677399 -
Knee Osteoarthritis Treatment With Peloidotherapy and Aquatic Exercise.
|
N/A | |
Active, not recruiting |
NCT04043819 -
Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis
|
Phase 1 | |
Recruiting |
NCT06000410 -
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
|
Phase 3 | |
Completed |
NCT05014542 -
Needling Techniques for Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05892133 -
Prehabilitation Effect on Function and Patient Satisfaction Following Total Knee Arthroplasty
|
N/A | |
Recruiting |
NCT05528965 -
Parallel Versus Perpendicular Technique for Genicular Radiofrequency
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Active, not recruiting |
NCT02003976 -
A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone
|
N/A | |
Active, not recruiting |
NCT04017533 -
Stability of Uncemented Medially Stabilized TKA
|
N/A | |
Completed |
NCT04779164 -
The Relation Between Abdominal Obesity, Type 2 Diabetes Mellitus and Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT04006314 -
Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05423587 -
Genicular Artery Embolisation for Knee Osteoarthritis II
|
N/A | |
Enrolling by invitation |
NCT04145401 -
Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK
|
||
Active, not recruiting |
NCT03781843 -
Effects of Genicular Nerve Block in Knee Osteoarthritis
|
N/A | |
Completed |
NCT05974501 -
Pre vs Post Block in Total Knee Arthroplasty (TKA)
|
Phase 4 | |
Completed |
NCT05324163 -
Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
|
Phase 3 | |
Completed |
NCT05529914 -
Effects of Myofascial Release and Neuromuscular Training for Pes Anserine Syndrome Associated With Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05693493 -
Can Proprioceptive Knee Brace Improve Functional Outcome Following TKA?
|
N/A | |
Not yet recruiting |
NCT05510648 -
Evaluation of the Effect of High-intensity Laser Therapy in Knee Osteoarthritis
|
N/A |